Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) PT at $13.86

NeoGenomics, Inc. (NASDAQ:NEO) has been assigned a consensus rating of “Hold” from the twelve ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $14.5714.

Several research analysts recently commented on the company. Leerink Partners raised NeoGenomics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $12.00 to $25.00 in a research note on Wednesday, April 29th. Weiss Ratings raised NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 14th. Benchmark lifted their price objective on NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Friday. Wall Street Zen raised NeoGenomics from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Finally, TD Cowen restated a “buy” rating on shares of NeoGenomics in a research note on Wednesday, July 15th.

Insider Buying and Selling

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of the stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $11.29, for a total value of $59,916.03. Following the sale, the director directly owned 91,422 shares of the company’s stock, valued at approximately $1,032,154.38. This represents a 5.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On NeoGenomics

Several institutional investors have recently modified their holdings of NEO. First Horizon Corp grew its stake in shares of NeoGenomics by 52.6% during the fourth quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock worth $30,000 after purchasing an additional 865 shares in the last quarter. Headlands Technologies LLC acquired a new stake in NeoGenomics in the second quarter valued at $32,000. Caitong International Asset Management Co. Ltd raised its stake in NeoGenomics by 110.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock valued at $35,000 after buying an additional 1,556 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in NeoGenomics during the 4th quarter worth about $39,000. Finally, GAMMA Investing LLC lifted its holdings in NeoGenomics by 68.2% during the 4th quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock worth $42,000 after buying an additional 1,460 shares during the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics Stock Performance

Shares of NEO stock opened at $13.89 on Thursday. The firm has a 50 day moving average of $12.19 and a two-hundred day moving average of $10.65. The stock has a market capitalization of $1.81 billion, a PE ratio of -18.04 and a beta of 1.74. The company has a quick ratio of 4.06, a current ratio of 4.42 and a debt-to-equity ratio of 0.41. NeoGenomics has a 52 week low of $4.72 and a 52 week high of $15.57.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, April 28th. The medical research company reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. The business had revenue of $186.67 million for the quarter, compared to analyst estimates of $184.54 million. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The business’s quarterly revenue was up 11.3% compared to the same quarter last year. On average, research analysts predict that NeoGenomics will post -0.15 EPS for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.